A game-changing discovery in diagnosing genetic heart disease


Scientists at the Centenary Institute and Royal Prince Alfred Hospital have used state-of-the-art technology to significantly improve the diagnosis rate of a potentially deadly heart condition by up to 20 per cent.

Hypertrophic cardiomyopathy is a common genetic heart condition, which can affect both men and women at any age. It occurs when the heart muscle thickens – making it difficult for the heart to pump blood, and in some cases, results in sudden cardiac death.

Funded by NSW Health, Centenary scientists have used whole genome sequencing to explore hypertrophic cardiomyopathy in 58 Australian families, who are directly affected by the disease. Whole genome sequencing allowed the scientists to look at regions of patients’ genes which were previously not considered important.

Senior Researcher for Centenary Institute’s Molecular Cardiology Program and the University of Sydney, Dr Richard Bagnall is lead author of the paper, and believes it’s a game-changer in the field.

“This study shows we can use this incredible technology to diagnose hypertrophic cardiomyopathy in 2-out-of-10 more families. But there is a lot more information within those whole genomes we haven’t even had a look at yet, so this is really just scraping the surface of what’s possible,” Dr Bagnall said.

Head of Centenary’s Molecular Cardiology Program, Royal Prince Alfred Hospital cardiologist and University of Sydney Professor Chris Semsarian AM, has led the study, which he describes as a much more robust approach to genetic diagnosis in cardiomyopathy.

“This is precision medicine – finding the exact genetic change which is leading to disease in individual patients. The next step is to then link those genetic changes with the clinical features of these patients,” Professor Semsarian said

Read the full media release

Latest News

Prof John Rasko AO and collaborators publish world-first clinical stem cell study

Professor John Rasko AO has led a world-first clinical trial into engineered stem cell treatment use, treating 15 patients with steroid resistant acute graft-versus-host disease.

Enzyme insight could lead to new diabetes treatment

Centenary Institute research has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.

Reducing cirrhosis threat for high-risk drinkers

Research led by the Centenary Institute has shown that a healthy weight and coffee consumption may help lower the risk of high-risk drinkers developing alcohol-induced cirrhosis.


News Topics



Sign up for our latest News